Trimebutine

Trimebutine is a spasmolytic agent that regulates intestinal and colonic motility and relieves abdominal pain with antimuscarinic and weak mu opioid agonist effects. It is marketed for the treatment of irritable bowel syndrome (IBS) and lower gastrointestinal tract motility disorders, with IBS being one of the most common multifactorial GI disorders. It is used to restore normal bowel function and is commonly present in pharmaceutical mixtures as trimebutine maleate salt form. Trimebutine is not a FDA-approved drug, but it is available in Canada and several other international countries. It is grouped under the following drug class(es): Anticholinergics. Its therapeutic use is listed as gastrointestinal agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Transacalm, Modulon and Trimebutinum. Its PubChem CID is 5573.

CAS No 39133-31-8
Molecular Formula C22H29NO5
Molecular Weight 387.5 g/mol
Synonyms [2-(dimethylamino)-2-phenylbutyl] 3,4,5-trimethoxybenzoate

Frequently Asked Questions